Speaking on a conference call with investors, Merck's research chief Roger Perlmutter said the company has secured manufacturing capability to make "many millions of doses" of the drug before year end. The experimental drug is currently in phase 2 trials
Merck plans large trials of antiviral Covid-19 drug in September
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.